Spots Global Cancer Trial Database for stage iii melanoma
Every month we try and update this database with for stage iii melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | NCT00091143 | Melanoma (Skin) | gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy | NCT00897520 | Melanoma (Skin) | recombinant int... proteomic profi... immunoenzyme te... laboratory biom... | - 120 Years | Eastern Cooperative Oncology Group | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting | NCT05079113 | Stage III Melan... Stage IV Cutane... | 18 Years - | Case Comprehensive Cancer Center | ||
| Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00007969 | Melanoma (Skin) | Detox-B adjuvan... verteporfin | 18 Years - | National Cancer Institute (NCI) | |
| ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma | NCT00081042 | Melanoma (Skin) | paclitaxel albu... | 18 Years - | National Cancer Institute (NCI) | |
| Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00667901 | Melanoma (Skin) | riluzole protein express... reverse transcr... western blottin... immunohistochem... laboratory biom... pharmacological... neoadjuvant the... therapeutic con... | 18 Years - | Rutgers, The State University of New Jersey | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | NCT02073123 | Metastatic Mela... Stage III Melan... Stage IV Melano... | Indoximod Ipilimumab Nivolumab Pembrolizumab | 18 Years - | Lumos Pharma | |
| Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00667901 | Melanoma (Skin) | riluzole protein express... reverse transcr... western blottin... immunohistochem... laboratory biom... pharmacological... neoadjuvant the... therapeutic con... | 18 Years - | Rutgers, The State University of New Jersey | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00004025 | Melanoma (Skin) | aldesleukin dendritic cell-... | 18 Years - | National Cancer Institute (NCI) | |
| High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | NCT00003641 | Melanoma (Skin) | interferon alfa... observation | 18 Years - | Eastern Cooperative Oncology Group | |
| Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT) | NCT05445752 | Melanoma Stage ... | 18 Years - 90 Years | Hospital Universitario Virgen Macarena | ||
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | NCT00512798 | Brain and Centr... Melanoma Solid Tumor | PS-341 (VELCADE... temozolomide immunoenzyme te... PS-341 (VELCADE... Temozolomide | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma | NCT00002892 | Melanoma (Skin) | recombinant int... | - | National Cancer Institute (NCI) | |
| Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | NCT00471887 | Melanoma (Skin) | CP-675,206 | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin | NCT00453050 | Melanoma (Skin) Metastatic Canc... | imiquimod indocyanine gre... flow cytometry immunologic tec... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00085397 | Melanoma (Skin) | autologous dend... gp100 antigen therapeutic aut... | - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00004184 | Melanoma (Skin) | monoclonal anti... sargramostim alum adjuvant | 18 Years - | University of Alabama at Birmingham | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | NCT00602576 | Melanoma (Skin) | sorafenib tosyl... temozolomide | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00003346 | Melanoma (Skin) | acetaminophen acetylcysteine carmustine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin | NCT00453050 | Melanoma (Skin) Metastatic Canc... | imiquimod indocyanine gre... flow cytometry immunologic tec... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | NCT05289193 | Melanoma Melanoma Stage ... | PET Scan Nivolumab Ipilimumab Surgical Resect... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma | NCT00082875 | Stage III Melan... Stage IV Melano... | cilengitide pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT01851408 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00089362 | Male Breast Can... Recurrent Adeno... Recurrent Basal... Recurrent Breas... Recurrent Colon... Recurrent Esthe... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Melan... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Colon... Stage III Esthe... Stage III Gastr... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Melan... Stage III Midli... Stage III Mucoe... Stage III Ovari... Stage III Renal... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IIIB Brea... Stage IIIC Brea... Stage IV Adenoi... Stage IV Basal ... Stage IV Breast... Stage IV Colon ... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Melano... Stage IV Midlin... Stage IV Mucoep... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu... Untreated Metas... | alvespimycin hy... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma | NCT00060333 | Recurrent Melan... | radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00002817 | Melanoma (Skin) | sargramostim vaccinia-GM-CSF... | 18 Years - | National Cancer Institute (NCI) | |
| Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma | NCT01376713 | Stage III Melan... Stage IV Melano... | Ofatumumab Ofatumumab plus... | 18 Years - | Medical University of Vienna | |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes | NCT03551626 | Malignant Melan... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | NCT00278122 | Melanoma (Skin) | sargramostim paclitaxel | 18 Years - | University of Virginia | |
| Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | NCT00004022 | Melanoma (Skin) | aldesleukin autologous tumo... muromonab-CD3 therapeutic aut... surgical proced... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma | NCT00002781 | Melanoma (Skin) | boronophenylala... | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | NCT00074308 | Recurrent Melan... Stage III Melan... Stage IV Melano... Unspecified Adu... | imatinib mesyla... bevacizumab pharmacological... laboratory biom... | 21 Years - | National Cancer Institute (NCI) | |
| Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured | NCT00798629 | Melanoma (Skin) | Autologous dend... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Decitabine in Treating Patients With Advanced Solid Tumors | NCT00030615 | Male Breast Can... Recurrent Bladd... Recurrent Breas... Recurrent Melan... Stage III Melan... Stage IV Bladde... Stage IV Breast... Stage IV Melano... Unspecified Adu... | decitabine pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | NCT00512798 | Brain and Centr... Melanoma Solid Tumor | PS-341 (VELCADE... temozolomide immunoenzyme te... PS-341 (VELCADE... Temozolomide | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma | NCT00002781 | Melanoma (Skin) | boronophenylala... | 18 Years - | National Cancer Institute (NCI) | |
| Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00962845 | Melanoma (Skin) | hydroxychloroqu... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | NCT00945269 | Recurrent Melan... Stage III Melan... Stage IV Melano... | therapeutic aut... aldesleukin denileukin dift... biopsy immunohistochem... laboratory biom... polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma | NCT00005961 | Melanoma (Skin) | O6-benzylguanin... carmustine | 18 Years - | National Cancer Institute (NCI) | |
| Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg | NCT00003789 | Recurrent Melan... Stage III Melan... | isolated limb p... melphalan recombinant tum... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | NCT00436410 | Adrenocortical ... Breast Cancer Colorectal Canc... Gastrointestina... Kidney Cancer Liver Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Sarcoma | colloidal gold-... electron micros... pharmacological... conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | NCT01875653 | Stage IV Melano... Stage III Melan... | Autologous Dend... Autologous PBMC... | 18 Years - | Lisata Therapeutics, Inc. | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT00349206 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00866840 | Melanoma (Skin) | riluzole | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma | NCT00004104 | Melanoma (Skin) | liposomal inter... polyvalent mela... recombinant int... | 18 Years - 75 Years | NYU Langone Health | |
| Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00004184 | Melanoma (Skin) | monoclonal anti... sargramostim alum adjuvant | 18 Years - | University of Alabama at Birmingham | |
| Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | NCT00003715 | Melanoma (Skin) | BCG vaccine autologous tumo... recombinant int... chemotherapy cyclophosphamid... | 18 Years - 120 Years | AVAX Technologies | |
| Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118274 | Melanoma (Skin) | incomplete Freu... melanoma helper... multi-epitope m... tetanus toxoid ... cyclophosphamid... | 18 Years - 120 Years | University of Virginia | |
| Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma | NCT00002535 | Melanoma (Skin) | aldesleukin lymphokine-acti... therapeutic tum... cyclophosphamid... indomethacin | 17 Years - | National Cancer Institute (NCI) | |
| A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | NCT00661336 | Melanoma (Skin) | buthionine sulf... melphalan microarray anal... high performanc... laboratory biom... pharmacological... biopsy | 18 Years - | Duke University | |
| Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer | NCT00006022 | Kidney Cancer Melanoma (Skin) | aldesleukin bryostatin 1 | 18 Years - 120 Years | Virginia Commonwealth University | |
| Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 | NCT00070343 | Melanoma (Skin) | oblimersen sodi... dacarbazine | - | National Cancer Institute (NCI) | |
| Sargramostim (GM-CSF) + PD-1 | NCT04703426 | Unresectable Me... Metastatic Mela... Stage III Melan... Stage IV Melano... | Sargramostim (G... Pembrolizumab (... | 18 Years - | Dana-Farber Cancer Institute | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members | NCT00346008 | Melanoma (Skin) | mutation analys... high performanc... laboratory biom... questionnaire a... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma | NCT00003362 | Melanoma (Skin) | QS21 gp100 antigen incomplete Freu... sargramostim tyrosinase pept... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma | NCT01026051 | Stage III Melan... Stage IV Melano... | MKC1106-MT | 18 Years - | Mannkind Corporation | |
| Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors | NCT00004016 | Melanoma (Skin) Unspecified Adu... | recombinant int... | 18 Years - | University of Rochester | |
| Interferon Toxicities in Melanoma Treatment | NCT02794636 | Stage III Melan... | 18 Years - | Bristol-Myers Squibb | ||
| Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis | NCT00004196 | Melanoma (Skin) | recombinant int... lymphangiograph... Observation | 18 Years - 70 Years | University of Alabama at Birmingham | |
| S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma | NCT00898183 | Melanoma (Skin) | gene expression... polymorphism an... | 18 Years - | SWOG Cancer Research Network | |
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | NCT03719131 | Cutaneous Melan... Cutaneous Melan... Stage III Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... Unresectable Me... | Nivolumab Rituximab and H... Ipilimumab | 18 Years - | Emory University | |
| Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | NCT00667901 | Melanoma (Skin) | riluzole protein express... reverse transcr... western blottin... immunohistochem... laboratory biom... pharmacological... neoadjuvant the... therapeutic con... | 18 Years - | Rutgers, The State University of New Jersey | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma | NCT00037037 | Melanoma (Skin) | MAGE-10.A2 MART-1 antigen NY-ESO-1 peptid... sargramostim tyrosinase pept... | 18 Years - | National Cancer Institute (NCI) | |
| Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin | NCT00003444 | Melanoma (Skin) | recombinant int... radiation thera... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | NCT02721459 | Melanoma Skin Cancer | XL888 Vemurafenib Cobimetinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma | NCT00002535 | Melanoma (Skin) | aldesleukin lymphokine-acti... therapeutic tum... cyclophosphamid... indomethacin | 17 Years - | National Cancer Institute (NCI) | |
| Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members | NCT00346008 | Melanoma (Skin) | mutation analys... high performanc... laboratory biom... questionnaire a... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | NCT00119249 | Stage III Melan... Stage IV Melano... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 | NCT00070343 | Melanoma (Skin) | oblimersen sodi... dacarbazine | - | National Cancer Institute (NCI) | |
| Interferon Toxicities in Melanoma Treatment | NCT02794636 | Stage III Melan... | 18 Years - | Bristol-Myers Squibb | ||
| Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma | NCT00107159 | Melanoma (Skin) | autologous dend... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
